Dr. Schwartz’s vision is to establish highly innovative, transformative clinical translational research programs in the field of cancer therapy. Formerly Chief of Hematology and Oncology at Columbia University Irving Medical Center (CUIMC) and Deputy Director of the Herbert Irving Comprehensive Cancer Center, his post at Case CCC follows 30 years of extensive bench-top to bedside research in gastrointestinal cancers, melanoma, and sarcoma.
As the former Chief of the Melanoma and Sarcoma Service at Memorial Sloan-Kettering Cancer Center (MSKCC), he successfully brought together clinical researchers and basic scientists to establish a highly successful clinical research program that focused on translational clinical trials with small molecule inhibitors and targeted immunologic agents. More recently, Dr. Schwartz has developed novel therapies for rare cancers, especially sarcoma and uveal melanoma.
Alliance for Rare Cancers I Jedi Rare Cancer Foundation
P.O. Box 683501, Park City, Utah 84068
The Alliance for Rare Cancers is a fiscally sponsored program of the Jedi Rare Cancer Foundation, a 501(c)(3) nonprofit organization, accepting tax-deductible donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-2610819. All donations are tax deductible as allowed by law.I
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.